Tonix Pharmaceuticals, Inc.’s (NASDAQ: TNXP) ($TNXP) interview with Dr. Seth Lederman, MD, and CEO.

0
148

New to The Street’s TV Host Jane King, from the Nasdaq Marketplace studio, welcomes back Dr. Seth Lederman, MD, CEO at Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP), a clinical-stage biopharmaceutical Company. Dr. Lederman provides a corporate update on its clinical study on patents afflicted with Long-Covid. At the onset of the study, Long-covid symptoms appear heterogeneous, meaning they are not similar among those afflicted. However, the four main symptoms of Fibromyalgia, multi-site pain, fatigue, cognitive problems (Brain Fog), and sleep issues, are also typical with Long-Covid patients. 2/3 of Long-Covid patients have these overlapping symptoms common with Fibromyalgia. Tonix’s TNX-102 SL completed its Fibromyalgia FDA Phase 3 and is moving forward with the FDA for new drug approval. Dr. Lederman believes it could be about another year before FDA drug approval contingent on successful Phase 3 reconfirmation results. Tonix is moving forward with a Long-Covid prevail study for its TNX-102 SL to be completed in the first half of 2023 with the expectation of enrolling 470 patients in a double-blind, randomized placebo study. The results on these 470 people should give Tonix data showing that the TNX-102 SL can help those with Long-Covid. With each successful TNX-102 SL Long Covid study/trial, the Company expects to continue forward with the necessary FDA approvals. The economic hardships for individuals and the overall economy are a massive expense. President Biden, in April 2022, signed an Executive memo for all branches of Government to come up with a national response to handle Long-Covid. A Harvard health economist expects the economic losses to be around $3.7T. 20-30% of those who recovered from Covid now appear to have Long-Covid symptoms, which can last months or years. Doctors who don’t understand the problem are treating patients with opioid based drugs, which don’t help and could cause addiction issues. TNX-102 SL is non-addictive, has no opioid compounds, and improves sleep quality. The Fibromyalgia studies show that sleep quality is important to reducing fibromyalgia symptoms; the same quality sleep might be the key to resolving Long-Covid issues. The on-screen QR code is available during the show; download or visit Tonix Pharmaceuticals, Inc. – https://www.tonixpharma.com/.

To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv

Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet

Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/

Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/

Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet

About New to the Street: https://newtothestreet.com/

Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list